Who is sponsoring NCT00075673?

NCT00075673 is sponsored by Case Comprehensive Cancer Center.

What condition does NCT00075673 study?

NCT00075673 studies Breast Cancer.

What drugs are being tested in NCT00075673?

Interventions: celecoxib, vinorelbine ditartrate.

What is the status of NCT00075673?

NCT00075673 is currently TERMINATED.

Last reviewed 2020-07-23 · How we verify

A Phase I Study of Weekly Administration of Oral Navelbine in Combination With the COX-2 Inhibitor Celebrex in Relapsed and/or Metastatic Breast Cancer

NCT00075673 Phase 1 TERMINATED

RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy, such as vinorelbine, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining vinorelbine with celecoxib may kill more tumor cells. PURPOSE: Phase I trial to determine the effectiveness of combining vinorelbine with celecoxib in treating women who have relapsed or metastatic breast cancer.

Details

Lead sponsor	Case Comprehensive Cancer Center
Phase	Phase 1
Status	TERMINATED
Enrolment	6
Start date	2003-11
Completion	2005-02

Conditions

Breast Cancer

Interventions

celecoxib
vinorelbine ditartrate

Primary outcomes

Determine the maximum tolerated dose of vinorelbine and celecoxib in women with relapsed or metastatic breast cancer. — Courses (21 days) repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Countries

United States